Find disease awareness content and relevant supporting materials

Hip and knee osteoarthritis (HKOA) is a chronic disease characterized by joint pain that leads to reduced physical function and health-related quality of life (HRQoL). At present, no cure is available.

Hip and knee osteoarthritis (OA) are leading causes of global disability. Most research to date has focused on the knee, with results often extrapolated to the hip, and this extends to treatment recommendations in clinical guidelines

Objectives: To explore the relative contribution of cumulative physical workload, sociodemographic and lifestyle factors, as well as prior injury to hospitalization due to knee and hip OA.

Objectives: To assess the association of whole grain consumption with the risk of incident knee OA.

Flexion Therapeutics, Inc.announced that the FDA approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection...

Osteoarthritis (OA) affects 240 million people worldwide. Neuroimaging has been increasingly used to investigate brain changes in OA, however, there is considerable heterogeneity in reported results.

Regeneron Pharmaceuticals, Inc. announced positive topline results from a placebo-controlled Phase II/III study evaluating fasinumab in patients with moderate-to-severe osteoarthritis...

A new meta-analysis of 29 studies involving more than 4,500 patients with Knee Osteoarthritis found that intra-articular hyaluronic acid (HA)...

Ampio Pharmaceuticals has announced updates for the STRUT and STRIDE multiple injection studies with Ampion (aspartyl-alanyl diketopiperazine), for patients with...

Flexion Therapeutics, Inc.announced that the results from a post-hoc analysis of data from the pivotal Phase III trial of Zilretta...